SANTA ANA, Calif.--(BUSINESS WIRE)--Cold Genesys Inc., a clinical-stage oncolytic immunotherapy company, today announced the successful completion of a Series B financing co-led by Ally Bridge Group and WI Harper Group with participation from Whitesun Healthcare Ventures and Song Hong Fang. The insider-initiated $10 million Series B financing will advance Cold Genesys’ investigational oncolytic immunotherapy CG0070 in a pivotal study (BOND II) that is currently enrolling 122 patients with high-
| < Prev | Next > |
|---|
